Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05340504 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05340504 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 12 participants.
The verdict
NCT05340504, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research study evaluates the effects of anFDA-approved medication NAC in individuals with Bipolar Disorder. Participants in the study will will be assigned to two medication conditions and will take both NAC and a matched placebo. The order in which they take each medication will be random. Study medication will be taken for 14 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
Interventions
- DRUG Placebo
- DRUG N-Acetyl cysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-05-13 |
| Est. Completion | 2023-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05340504
The ClinicalTrials.gov registry entry for NCT05340504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05340504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05340504 about?
NCT05340504 is a clinical study titled "Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder". This research study evaluates the effects of anFDA-approved medication NAC in individuals with Bipolar Disorder. Participants in the study will will be assigned to two medication conditions and will take both NAC and a matched placebo. The order in which they take each medication will be random. Stu...
What is the current status of trial NCT05340504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-05-13. Estimated completion is 2023-06-21.
What interventions are being tested in trial NCT05340504?
The interventions under investigation include: Placebo (DRUG), N-Acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT05340504?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.